Transglutaminase Activity as a Possible Therapeutical Target in Neurodegenerative Diseases

Author(s): Martina Iannaccone, Federica Titta, Enrica Serretiello, Giulia De Vivo, Antonio Martin, Vittorio Gentile.

Journal Name: Recent Patents on CNS Drug Discovery (Discontinued)

Volume 8 , Issue 3 , 2013


Transglutaminases are ubiquitous enzymes which catalyze post-translational modifications of proteins. The main activity of these enzymes is the cross-linking of glutaminyl residues of a protein/peptide substrate to lysyl residues of a protein/peptide co-substrate. In addition to lysyl residues, other second nucleophilic co-substrates may include monoamines or polyamines (to form mono- or bi-substituted /crosslinked adducts) or –OH groups (to form ester linkages). In absence of co-substrates, the nucleophile may be water, resulting in the net deamidation of the glutaminyl residue. Transglutaminase activity has been suggested to be involved in molecular mechanisms responsible for both physiological or pathological processes. For example, neurodegenerative diseases, such as Alzheimer’s Disease, Parkinson’s Disease, supranuclear palsy, Huntington’s Disease and other polyglutamine diseases, are characterized in part by aberrant cerebral transglutaminase activity and by increased cross-linked proteins in affected brains. This review focuses on the possible molecular mechanisms responsible for such diseases and on the possible therapeutic effects of selective transglutaminase inhibitors for patients with diseases characterized by aberrant transglutaminase activity. The article presents some promising patents on the transglutaminase activity.

Keywords: Cystamine, neurodegenerative diseases, post-translational modifications of proteins, protein aggregation, transglutaminases, transglutaminase inhibitors.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2013
Page: [235 - 242]
Pages: 8
DOI: 10.2174/1574889808666131128105630
Price: $58

Article Metrics

PDF: 15